Cantor Fitzgerald Reiterates Neutral Rating for CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP)‘s stock had its “neutral” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued on Wednesday,Benzinga reports.

Several other equities research analysts also recently weighed in on the company. Stifel Nicolaus decreased their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research report on Thursday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. The Goldman Sachs Group decreased their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Finally, Citigroup dropped their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average target price of $74.40.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP opened at $50.46 on Wednesday. The stock has a 50-day simple moving average of $42.16 and a 200-day simple moving average of $46.07. The stock has a market capitalization of $4.33 billion, a P/E ratio of -11.55 and a beta of 1.67. CRISPR Therapeutics has a 1 year low of $36.52 and a 1 year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Analysts predict that CRISPR Therapeutics will post -5.03 earnings per share for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.10% of the stock is owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of large investors have recently bought and sold shares of CRSP. Highline Wealth Partners LLC bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $39,000. Western Pacific Wealth Management LP boosted its position in CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in CRISPR Therapeutics during the 3rd quarter valued at approximately $40,000. Darwin Wealth Management LLC bought a new position in CRISPR Therapeutics during the 3rd quarter worth $43,000. Finally, Eastern Bank acquired a new stake in CRISPR Therapeutics in the third quarter worth $70,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.